Immunitybio Valuation
| IBRX Stock | USD 2.75 0.08 2.83% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Immunitybio retains a regular Real Value of $4.79 per share. The prevalent price of the firm is $2.75. Our model calculates the value of Immunitybio from evaluating the firm fundamentals such as Return On Asset of -0.56, shares owned by insiders of 74.11 %, and Operating Margin of (3.90) % as well as inspecting its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Immunitybio's price fluctuation is unstable at this time. Calculation of the real value of Immunitybio is based on 3 months time horizon. Increasing Immunitybio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Immunitybio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Immunitybio Stock. However, Immunitybio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.75 | Real 4.79 | Hype 2.74 | Naive 2.98 |
The intrinsic value of Immunitybio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Immunitybio's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Immunitybio helps investors to forecast how Immunitybio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Immunitybio more accurately as focusing exclusively on Immunitybio's fundamentals will not take into account other important factors: Immunitybio Total Value Analysis
Immunitybio is currently projected to have valuation of 2.88 B with market capitalization of 2.43 B, debt of 504.17 M, and cash on hands of 82.94 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Immunitybio fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.88 B | 2.43 B | 504.17 M | 82.94 M |
Immunitybio Investor Information
About 74.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.57. Immunitybio had not issued any dividends in recent years. Based on the analysis of Immunitybio's profitability, liquidity, and operating efficiency, Immunitybio is not in a good financial situation at this time. It has a very high odds of going through financial crisis in August.Immunitybio Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Immunitybio has an asset utilization ratio of 3.85 percent. This suggests that the Company is making $0.0385 for each dollar of assets. An increasing asset utilization means that Immunitybio is more efficient with each dollar of assets it utilizes for everyday operations.Immunitybio Ownership Allocation
Immunitybio has a total of 882.62 Million outstanding shares. Immunitybio retains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 74.11 (percent) of Immunitybio outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Immunitybio Profitability Analysis
The company reported the previous year's revenue of 14.74 M. Net Loss for the year was (413.64 M) with profit before overhead, payroll, taxes, and interest of 31.16 M.About Immunitybio Valuation
Our relative valuation model uses a comparative analysis of Immunitybio. We calculate exposure to Immunitybio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Immunitybio's related companies.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. The company was founded in 2014 and is based in San Diego, California. Immunitybio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 740 people.
Immunitybio Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 700.4 M |
Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.